Sensus Healthcare (NASDAQ:SRTS – Get Rating) posted its quarterly earnings data on Thursday. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.06 by $0.91, MarketWatch Earnings reports. Sensus Healthcare had a net margin of 15.23% and a return on equity of 18.88%. During the same quarter in the prior year, the company earned ($0.07) earnings per share.
NASDAQ SRTS traded up $0.64 on Friday, reaching $7.80. 528,174 shares of the company’s stock traded hands, compared to its average volume of 216,376. The firm has a market cap of $130.10 million, a price-to-earnings ratio of 6.09 and a beta of 0.52. The stock has a 50 day moving average price of $9.39 and a 200-day moving average price of $7.95. Sensus Healthcare has a fifty-two week low of $3.08 and a fifty-two week high of $11.96.
In other Sensus Healthcare news, COO Nicolas Soro sold 10,000 shares of the company’s stock in a transaction dated Wednesday, March 9th. The shares were sold at an average price of $10.20, for a total value of $102,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph C. Sardano sold 44,782 shares of the company’s stock in a transaction dated Friday, March 11th. The stock was sold at an average price of $10.11, for a total transaction of $452,746.02. The disclosure for this sale can be found here. Insiders have sold 114,056 shares of company stock valued at $1,151,818 over the last 90 days. 24.30% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. a new stake in shares of Sensus Healthcare during the fourth quarter purchased worth about $141,000. Virtu Financial LLC increased its stake in shares of Sensus Healthcare by 88.2% during the fourth quarter. Virtu Financial LLC now owns 21,756 shares of the company’s stock worth $157,000 after purchasing an additional 10,195 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth about $281,000. State Street Corp increased its stake in shares of Sensus Healthcare by 299.4% during the fourth quarter. State Street Corp now owns 42,287 shares of the company’s stock worth $305,000 after purchasing an additional 31,700 in the last quarter. Finally, Morgan Stanley increased its stake in shares of Sensus Healthcare by 340.4% during the first quarter. Morgan Stanley now owns 44,894 shares of the company’s stock worth $172,000 after purchasing an additional 34,699 shares in the last quarter. 20.49% of the stock is owned by institutional investors and hedge funds.
Several research firms have recently commented on SRTS. Zacks Investment Research downgraded shares of Sensus Healthcare from a “buy” rating to a “hold” rating in a research note on Tuesday. Maxim Group restated a “buy” rating and set a $14.00 target price on shares of Sensus Healthcare in a research report on Friday. HC Wainwright boosted their target price on shares of Sensus Healthcare from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Thursday, March 3rd. Finally, TheStreet upgraded shares of Sensus Healthcare from a “c” rating to a “b-” rating in a research report on Friday, February 11th.
Sensus Healthcare Company Profile (Get Rating)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids ; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Receive News & Ratings for Sensus Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sensus Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.